NCT04311294View on ClinicalTrials.gov

Development of a Selective ALDH2 Inhibitor to Treat AUD

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

March 31, 2022

Conditions
Alcohol Use Disorder
Interventions
DRUG

ANS-6637 Low Dose

ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.

DRUG

ANS-6637 High Dose

ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.

DRUG

Matched Placebo

ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.

Trial Locations (1)

90095

UCLA Addictions Lab, Los Angeles

Sponsors

Collaborators (1)

Amygdala Neurosciences
All Listed Sponsors
collaborator

Amygdala Neurosciences

UNKNOWN

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of California, Los Angeles

OTHER

NCT04311294 - Development of a Selective ALDH2 Inhibitor to Treat AUD | Biotech Hunter | Biotech Hunter